Emergent BioSolutions (EBS) Capital Expenditures (2010 - 2026)

Emergent BioSolutions has reported Capital Expenditures for 17 years, with the latest figure at $2.1 million in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 27.59% year-over-year to $2.1 million in Q2 2026; TTM through Jun 2026 was $11.8 million, a 15.71% decrease from a year earlier, with the FY2025 full-year figure at $13.8 million, down 39.74% from the prior year.
• Capital Expenditures was $2.1 million for Q2 2026 at Emergent BioSolutions, down from $2.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $179.4 million in Q3 2022, with the low at $1.7 million in Q4 2024.
• Average Capital Expenditures over 5 years is $19.8 million, with a median of $5.8 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 225.0% in 2022, then plunged 92.98% in 2023.
• Over 5 years, Capital Expenditures stood at $179.4 million in 2022, then slumped by 93.65% to $11.4 million in 2023, then tumbled by 85.09% to $1.7 million in 2024, then soared by 129.41% to $3.9 million in 2025, then plunged by 46.15% to $2.1 million in 2026.
• The last three Capital Expenditures figures came in at $2.1 million (Q2 2026), $2.4 million (Q1 2026), and $3.9 million (Q4 2025), per Business Quant data.